Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe

Por Luna Colagrossi, Lucas E. Hermans, Romina Salpini, Domenico Di Carlo, Suzan D. Pas, Marta Alvarez, Ziv Ben-Ari, Greet Boland, Bianca Bruzzone, Nicola Coppola, Carole Seguin-Devaux, Tomasz Dyda, Federico Garcia, Rolf Kaiser, Sukran Köse, Henrik Krarup, Ivana Lazarevic, Maja M. Lunar, Sarah Maylin, Valeria Micheli, Orna Mor, Simona Paraschiv, Dimitros Paraskevis, Mario Poljak, Elisabeth Puchhammer-Stöckl, François Simon, Maja Stanojevic, Kathrine Stene-Johansen, Nijaz Tihic, Pascale Trimoulet, Jens Verheyen, Adriana Vince, Snjezana Zidovec Lepej, Nina Weis, Tülay Yalcinkaya, Charles A. B. Boucher, Annemarie M. J. Wensing, Carlo F. Perno, Valentina Svicher, on behalf of the HEPVIR working group of the European Society for translational antiviral research (ESAR)
Publicado em 2018-06-01